Item 1. Financial Statements
167K characters. Original on sec.gov ·
Item 1. Financial Statements
| Consolidated Condensed Statements of Operations | |||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions, Except Per Share Amounts; Unaudited) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Net revenue | $ | 13,653 | $ | 13,284 | $ | 39,179 | $ | 38,841 | ||||||||||||||||||
| Cost of sales | 8,435 | 11,287 | 25,747 | 27,080 | ||||||||||||||||||||||
| Gross profit | 5,218 | 1,997 | 13,432 | 11,761 | ||||||||||||||||||||||
| Research and development | 3,231 | 4,049 | 10,555 | 12,670 | ||||||||||||||||||||||
| Marketing, general, and administrative | 1,129 | 1,383 | 3,450 | 4,268 | ||||||||||||||||||||||
| Restructuring and other charges | 175 | 5,622 | 2,221 | 6,913 | ||||||||||||||||||||||
| Operating expenses | 4,535 | 11,054 | 16,226 | 23,851 | ||||||||||||||||||||||
| Operating income (loss) | 683 | (9,057) | (2,794) | (12,090) | ||||||||||||||||||||||
| Gains (losses) on equity investments, net | 221 | (159) | 611 | (74) | ||||||||||||||||||||||
| Interest and other, net | 3,670 | 130 | 3,402 | 355 | ||||||||||||||||||||||
| Income (loss) before taxes | 4,574 | (9,086) | 1,219 | (11,809) | ||||||||||||||||||||||
| Provision for (benefit from) taxes | 304 | 7,903 | 860 | 7,271 | ||||||||||||||||||||||
| Net income (loss) | 4,270 | (16,989) | 359 | (19,080) | ||||||||||||||||||||||
| Less: net income (loss) attributable to non-controlling interests | 207 | (350) | 35 | (450) | ||||||||||||||||||||||
| Net income (loss) attributable to Intel | $ | 4,063 | $ | (16,639) | $ | 324 | $ | (18,630) | ||||||||||||||||||
| Earnings (loss) per share attributable to Intel—basic | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) | ||||||||||||||||||
| Earnings (loss) per share attributable to Intel—diluted****¹ | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) | ||||||||||||||||||
| Weighted average shares of common stock outstanding: | ||||||||||||||||||||||||||
| Basic | 4,514 | 4,292 | 4,424 | 4,267 | ||||||||||||||||||||||
| Diluted | 4,531 | 4,292 | 4,434 | 4,267 |
1 For the three and nine months ended September 27, 2025, earnings (loss) per share attributable to Intel-diluted has been calculated by adjusting net income (loss) attributable to Intel for the loss of $2 million related to the mark-to-market of that portion of the derivative liability that is attributable to 342 thousand contingent Escrowed Shares that were included in the weighted average shares of common stock outstanding-diluted during the period.
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Operations | 3 |
| Consolidated Condensed Statements of Comprehensive Income (Loss) | |||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions; Unaudited) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Net income (loss) | $ | 4,270 | $ | (16,989) | $ | 359 | $ | (19,080) | ||||||||||||||||||
| Changes in other comprehensive income (loss), net of tax: | ||||||||||||||||||||||||||
| Net unrealized holding gains (losses) on derivatives | (48) | 512 | 727 | 32 | ||||||||||||||||||||||
| Actuarial valuation and other pension benefits (expenses), net | 1 | — | 2 | — | ||||||||||||||||||||||
| Translation adjustments and other | 1 | (1) | 1 | (2) | ||||||||||||||||||||||
| Other comprehensive income (loss) | (46) | 511 | 730 | 30 | ||||||||||||||||||||||
| Total comprehensive income (loss) | 4,224 | (16,478) | 1,089 | (19,050) | ||||||||||||||||||||||
| Less: comprehensive income (loss) attributable to non-controlling interests | 207 | (350) | 35 | (450) | ||||||||||||||||||||||
| Total comprehensive income (loss) attributable to Intel | $ | 4,017 | $ | (16,128) | $ | 1,054 | $ | (18,600) | ||||||||||||||||||
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Comprehensive Income (Loss) | 4 |
| Consolidated Condensed Balance Sheets | |||||
| (In Millions; Unaudited) | Sep 27, 2025 | Dec 28, 2024 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 11,141 | $ | 8,249 | ||||||||||
| Short-term investments | 19,794 | 13,813 | ||||||||||||
| Accounts receivable, net | 3,202 | 3,478 | ||||||||||||
| Inventories | 11,489 | 12,198 | ||||||||||||
| Other current assets | 6,105 | 9,586 | ||||||||||||
| Total current assets | 51,731 | 47,324 | ||||||||||||
| Property, plant, and equipment, net of accumulated depreciation of $105,063 ($102,193 as of December 28, 2024) | 105,047 | 107,919 | ||||||||||||
| Equity investments | 8,667 | 5,383 | ||||||||||||
| Goodwill | 23,912 | 24,693 | ||||||||||||
| Identified intangible assets, net | 2,877 | 3,691 | ||||||||||||
| Other long-term assets | 12,280 | 7,475 | ||||||||||||
| Total assets | $ | 204,514 | $ | 196,485 | ||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 10,268 | $ | 12,556 | ||||||||||
| Accrued compensation and benefits | 3,756 | 3,343 | ||||||||||||
| Short-term debt | 2,496 | 3,729 | ||||||||||||
| Income taxes payable | 825 | 1,756 | ||||||||||||
| Other accrued liabilities | 14,952 | 14,282 | ||||||||||||
| Total current liabilities | 32,297 | 35,666 | ||||||||||||
| Debt | 44,057 | 46,282 | ||||||||||||
| Other long-term liabilities | 11,430 | 9,505 | ||||||||||||
| Contingencies (Note 13) | ||||||||||||||
| Stockholders’ equity: | ||||||||||||||
| Common stock and capital in excess of par value, 4,766 issued and outstanding (4,330 issued and outstanding as of December 28, 2024) | 56,755 | 50,949 | ||||||||||||
| Accumulated other comprehensive income (loss) | 19 | (711) | ||||||||||||
| Retained earnings | 49,602 | 49,032 | ||||||||||||
| Total Intel stockholders' equity | 106,376 | 99,270 | ||||||||||||
| Non-controlling interests | 10,354 | 5,762 | ||||||||||||
| Total stockholders' equity | 116,730 | 105,032 | ||||||||||||
| Total liabilities and stockholders’ equity | $ | 204,514 | $ | 196,485 |
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Balance Sheets | 5 |
| Consolidated Condensed Statements of Cash Flows | |||||
| Nine Months Ended | ||||||||||||||
| (In Millions; Unaudited) | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||
| Cash and cash equivalents, beginning of period | $ | 8,249 | $ | 7,079 | ||||||||||
| Cash flows provided by (used for) operating activities: | ||||||||||||||
| Net income (loss) | 359 | (19,080) | ||||||||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||||||||
| Depreciation | 7,971 | 7,651 | ||||||||||||
| Share-based compensation | 1,896 | 2,759 | ||||||||||||
| Restructuring and other charges | 372 | 3,626 | ||||||||||||
| Amortization of intangibles | 708 | 1,081 | ||||||||||||
| (Gains) losses on equity investments, net | (611) | 75 | ||||||||||||
| Mark-to-market (gains) losses on obligation to issue Escrowed Shares | 1,687 | — | ||||||||||||
| (Gains) losses on divestitures | (5,355) | — | ||||||||||||
| Deferred taxes | 123 | 6,368 | ||||||||||||
| Impairments and net (gain) loss on retirement of property, plant, and equipment | 465 | 2,290 | ||||||||||||
| Changes in assets and liabilities: | ||||||||||||||
| Accounts receivable | 162 | 282 | ||||||||||||
| Inventories | (9) | (969) | ||||||||||||
| Accounts payable | (281) | 566 | ||||||||||||
| Accrued compensation and benefits | 541 | 1,384 | ||||||||||||
| Income taxes | (1,196) | (930) | ||||||||||||
| Other assets and liabilities | (1,423) | 20 | ||||||||||||
| Total adjustments | 5,050 | 24,203 | ||||||||||||
| Net cash provided by (used for) operating activities | 5,409 | 5,123 | ||||||||||||
| Cash flows provided by (used for) investing activities: | ||||||||||||||
| Additions to property, plant, and equipment | (11,158) | (18,110) | ||||||||||||
| Proceeds from capital-related government incentives | 1,018 | 725 | ||||||||||||
| Purchases of short-term investments | (16,401) | (31,519) | ||||||||||||
| Maturities and sales of short-term investments | 10,964 | 34,268 | ||||||||||||
| Sales of equity investments | 642 | 503 | ||||||||||||
| Proceeds from divestitures, net | 6,186 | — | ||||||||||||
| Other investing | 494 | (359) | ||||||||||||
| Net cash provided by (used for) investing activities | (8,255) | (14,492) | ||||||||||||
| Cash flows provided by (used for) financing activities: | ||||||||||||||
| Issuance of commercial paper, net of issuance costs | 3,493 | 7,349 | ||||||||||||
| Repayment of commercial paper | (3,493) | (7,349) | ||||||||||||
| Partner contributions | 3,652 | 12,278 | ||||||||||||
| Net proceeds from sales of subsidiary shares | 922 | — | ||||||||||||
| Additions to property, plant, and equipment | (2,493) | (741) | ||||||||||||
| Issuance of long-term debt, net of issuance costs | — | 2,975 | ||||||||||||
| Repayment of debt | (3,750) | (2,288) | ||||||||||||
| Proceeds from sales of common stock through employee equity incentive plans | 777 | 986 | ||||||||||||
| Net proceeds attributed to common stock and warrants issued | 3,737 | — | ||||||||||||
| Net proceeds attributed to obligation to issue Escrowed Shares | 3,945 | — | ||||||||||||
| Payment of dividends to stockholders | — | (1,599) | ||||||||||||
| Other financing | (1,052) | (536) | ||||||||||||
| Net cash provided by (used for) financing activities | 5,738 | 11,075 | ||||||||||||
| Net increase (decrease) in cash and cash equivalents | 2,892 | 1,706 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 11,141 | $ | 8,785 | ||||||||||
| Non-cash supplemental disclosures: | ||||||||||||||
| Acquisition of property, plant, and equipment1 | $ | 5,068 | $ | 6,595 | ||||||||||
| Recognition of capital-related government incentives | $ | 6,094 | $ | 2,211 | ||||||||||
| Cash paid during the period for: | ||||||||||||||
| Interest, net of capitalized interest | $ | 1,156 | $ | 1,099 | ||||||||||
| Income taxes, net of refunds | $ | 1,939 | $ | 1,880 | ||||||||||
1 Includes $1,301 million with extended payment terms of greater than 90 days in the nine months ended September 27, 2025.
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Cash Flows | 6 |
| Consolidated Condensed Statements of Stockholders' Equity | |||||
| (In Millions, Except Per Share Amounts; Unaudited) | Common Stock and Capital in Excess of Par Value | Accumulated Other Comprehensive Income (Loss) | Retained Earnings****1 | Non-Controlling Interests | Total | |||||||||||||||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||
| Balance as of June 28, 2025 | 4,377 | $ | 52,334 | $ | 65 | $ | 45,484 | $ | 7,868 | $ | 105,751 | |||||||||||||||||||||||||||
| Net income (loss) | — | — | — | 4,063 | 207 | 4,270 | ||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | (46) | — | — | (46) | ||||||||||||||||||||||||||||||||
| Net proceeds from stock issuances and warrants2 | 362 | 3,758 | — | — | — | 3,758 | ||||||||||||||||||||||||||||||||
| Net proceeds from sales of subsidiary shares and partner contributions | — | 60 | — | — | 2,276 | 2,336 | ||||||||||||||||||||||||||||||||
| Partner distributions | — | — | — | — | (68) | (68) | ||||||||||||||||||||||||||||||||
| Employee equity incentive plans and other | 32 | 286 | — | — | — | 286 | ||||||||||||||||||||||||||||||||
| Share-based compensation | — | 477 | — | — | 71 | 548 | ||||||||||||||||||||||||||||||||
| Restricted stock unit withholdings | (5) | (160) | — | 55 | — | (105) | ||||||||||||||||||||||||||||||||
| Balance as of September 27, 2025 | 4,766 | $ | 56,755 | $ | 19 | $ | 49,602 | $ | 10,354 | $ | 116,730 | |||||||||||||||||||||||||||
| Balance as of June 29, 2024 | 4,276 | $ | 49,763 | $ | (696) | $ | 66,162 | $ | 5,205 | $ | 120,434 | |||||||||||||||||||||||||||
| Net income (loss) | — | — | — | (16,639) | (350) | (16,989) | ||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | 511 | — | — | 511 | ||||||||||||||||||||||||||||||||
| Net proceeds from partner contributions | — | — | — | — | 417 | 417 | ||||||||||||||||||||||||||||||||
| Employee equity incentive plans and other | 38 | 355 | — | — | — | 355 | ||||||||||||||||||||||||||||||||
| Share-based compensation | — | 740 | — | — | 60 | 800 | ||||||||||||||||||||||||||||||||
| Restricted stock unit withholdings | (5) | (193) | — | 65 | — | (128) | ||||||||||||||||||||||||||||||||
| Cash dividends declared ($0.13 per share of common stock) | — | — | — | (536) | — | (536) | ||||||||||||||||||||||||||||||||
| Balance as of September 28, 2024 | 4,309 | $ | 50,665 | $ | (185) | $ | 49,052 | $ | 5,332 | $ | 104,864 | |||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||
| Balance as of December 28, 2024 | 4,330 | $ | 50,949 | $ | (711) | $ | 49,081 | $ | 5,762 | $ | 105,081 | |||||||||||||||||||||||||||
| Net income (loss) | — | — | — | 324 | 35 | 359 | ||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | 730 | — | — | 730 | ||||||||||||||||||||||||||||||||
| Net proceeds from stock issuances and warrants2 | 362 | 3,758 | — | — | — | 3,758 | ||||||||||||||||||||||||||||||||
| Net proceeds from sales of subsidiary shares and partner contributions | — | 58 | — | — | 4,516 | 4,574 | ||||||||||||||||||||||||||||||||
| Partner distributions | — | — | — | — | (159) | (159) | ||||||||||||||||||||||||||||||||
| Employee equity incentive plans and other | 88 | 777 | — | — | — | 777 | ||||||||||||||||||||||||||||||||
| Share-based compensation | — | 1,696 | — | — | 200 | 1,896 | ||||||||||||||||||||||||||||||||
| Restricted stock unit withholdings | (14) | (483) | — | 197 | — | (286) | ||||||||||||||||||||||||||||||||
| Balance as of September 27, 2025 | 4,766 | $ | 56,755 | $ | 19 | $ | 49,602 | $ | 10,354 | $ | 116,730 | |||||||||||||||||||||||||||
| Balance as of December 30, 2023 | 4,228 | $ | 36,649 | $ | (215) | $ | 69,156 | $ | 4,375 | $ | 109,965 | |||||||||||||||||||||||||||
| Net income (loss) | — | — | — | (18,630) | (450) | (19,080) | ||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | 30 | — | — | 30 | ||||||||||||||||||||||||||||||||
| Net proceeds from partner contributions | — | 11,012 | — | — | 1,266 | 12,278 | ||||||||||||||||||||||||||||||||
| Employee equity incentive plans and other | 96 | 986 | — | — | — | 986 | ||||||||||||||||||||||||||||||||
| Share-based compensation | — | 2,618 | — | — | 141 | 2,759 | ||||||||||||||||||||||||||||||||
| Restricted stock unit withholdings | (15) | (600) | — | 125 | — | (475) | ||||||||||||||||||||||||||||||||
| Cash dividends declared ($0.38 per share of common stock) | — | — | — | (1,599) | — | (1,599) | ||||||||||||||||||||||||||||||||
| Balance as of September 28, 2024 | 4,309 | $ | 50,665 | $ | (185) | $ | 49,052 | $ | 5,332 | $ | 104,864 | |||||||||||||||||||||||||||
1 The retained earnings balance as of December 28, 2024 includes an opening balance adjustment made as a result of the adoption of a new accounting standard in 2025.
2 Includes $110 million of allocated proceeds to warrants from the Warrant and Common Stock Agreement with the U.S. government.
See accompanying notes.
![]() | Financial Statements | Consolidated Condensed Statements of Stockholders' Equity | 7 |
| Notes to Consolidated Condensed Financial Statements | |||||
| Note 1 : | Basis of Presentation |
We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2024 Form 10-K.
We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with our 2024 Form 10-K, which includes additional information on our significant accounting policies, as well as the methods and assumptions used in our estimates, and our Q2 2025 Form 10-Q, which discusses the critical accounting estimates that supplement the significant accounting policies outlined in "Note 2: Accounting Policies" within Notes to Consolidated Financial Statements within our 2024 Form 10-K.
| Note 2 : | Operating Segments |
In the first quarter of 2025, we made an organizational change to integrate our Networking and Edge (NEX) business into CCG and DCAI and modified our segment reporting to align to this and certain other business reorganizations. All prior period segment data have been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance starting in fiscal year 2025. Additionally, effective September 12, 2025, we completed the divestiture of 51% of Altera. As of that date, Altera's results of operations are no longer included in our consolidated or segment results. Altera's financial results were included within our "all other" category for all periods presented through September 11, 2025. There are no changes to our Consolidated Condensed Financial Statements for any prior periods resulting from our organizational change in the first quarter of 2025 or the Altera transaction, which is further described below.
We organize and manage our business as follows:
**▪**Intel Products:
**▪**Client Computing Group (CCG)
**▪**Data Center and AI (DCAI)
**▪**Intel Foundry
**▪**All Other
**▪**Mobileye
**▪**Other
CCG, DCAI, and Intel Foundry qualify as reportable operating segments. When we enter into federal contracts, they are aligned to the sponsoring operating segment.
The accounting policies applied to our segments follow those applied to Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows:
Intel Products: CCG and DCAI
**▪**Segment revenue: consists of revenues from external customers. Our Intel Products operating segments represent most of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture.
**▪**Segment expenses: consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing expenses, product development costs, allocated expenses as described below, and direct operating expenses.
Intel Foundry
**▪**Segment revenue: consists substantially of intersegment product and services revenue for wafer fabrication, substrates and other related products, and services sold to Intel Products and certain other Intel internal businesses. We recognize intersegment revenue based on the completion of performance obligations. Product revenue is recognized upon transfer of ownership, which is generally at the completion of wafer sorting. Backend service revenue is recognized upon the completion of assembly and test milestones, which approximates the recognition of revenue over the service period. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third-party foundry and assembly and test revenues from external customers that totaled $32 million in the three months ended September 27, 2025 and $85 million in the first nine months of 2025, compared to $55 million in the three months ended September 28, 2024, and $107 million in the first nine months of 2024.
![]() | Financial Statements | Notes to Financial Statements | 8 |
**▪**Segment expenses: consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing include excess capacity charges, if any.
All Other
Our "all other" category includes the results of operations from other non-reportable segments not otherwise presented, including our Mobileye business, our IMS business, start-up businesses that support our initiatives, and historical results of operations from divested businesses, including Altera. Effective September 12, 2025, Altera, previously a wholly-owned subsidiary, was deconsolidated from our consolidated financial statements following the closing of the sale of 51% of Altera's issued and outstanding common stock. Altera's financial results of operations were included in our "all other" category through September 11, 2025. As of September 12, 2025, our retained interest in Altera is accounted for as an equity method investment. See "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information. The financial results of our "all other" category include intersegment product and services revenue and intersegment expenses primarily between Altera and our Intel Foundry segment.
We allocate operating expenses from our sales and marketing group to the Intel Products operating segments and allocate substantially all our operating expenses from our general and administration groups to our reportable operating segments.
We estimate that the substantial majority of our consolidated depreciation expense in the first nine months of 2025 and 2024 was incurred by Intel Foundry. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products or other customers. As a result, it is impracticable to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss).
We do not allocate the following corporate operating expenses to our operating segments:
**▪**restructuring and other charges;
**▪**share-based compensation;
**▪**certain impairment charges; and
**▪**certain acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill.
We do not allocate the following non-operating items to our operating segments:
**▪**gains and losses from equity investments;
**▪**interest and other income; and
**▪**income taxes.
Our Chief Executive Officer is our CODM. The CODM uses segment revenue and segment operating income (loss) to evaluate each segment's performance and allocate resources. These financial measures are utilized during our budgeting and forecasting process to assess profitability and enable decision making regarding strategic initiatives, capital investments, and personnel across all operating segments. Segment operating results regularly reviewed by our CODM also include total cost of sales and operating expenses directly attributable to each segment. Prior to the second quarter of 2025, our CODM regularly reviewed cost of sales and operating expenses, on a discrete basis, attributable to each segment. We have recast prior period segment operating results to reflect the significant segment-level expenses as currently reviewed by our CODM. We centrally manage all procurement, treasury, and asset management functions across the enterprise and do not maintain separate balance sheets by segment within our systems of record, nor does our CODM receive total asset information by segment for purposes of assessing segment performance and allocating resources.
Intersegment eliminations: Intersegment sales and related gross profit on inventory recorded at the end of the period or sold through to third-party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies, respectively. Thus, certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves, which are determined and recorded based on our accounting policies for Intel as a whole but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified which relates to neither Intel Products operating segments nor Intel Foundry, the reserve is recognized as activity within the intersegment eliminations for Intel on a consolidated basis.
Reporting units and goodwill reallocation: As a result of modifying our segment reporting in the first quarter of 2025, we reallocated goodwill among our affected reporting units, which generally align to our operating segment structure, on a relative fair value basis. We performed a goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization, concluding that goodwill was not impaired.
As a result of modifying our segment reporting in the first quarter of 2024, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded based on our pre-reorganization impairment test that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of $222 million in the first quarter of 2024 related to our new Intel Foundry reporting unit as the estimated fair value of the new reporting unit was lower than the assigned carrying value. Intel Foundry had no remaining allocated goodwill as of March 30, 2024, or for any subsequent reporting period.
![]() | Financial Statements | Notes to Financial Statements | 9 |
Net revenue, cost of sales and operating expenses, and operating income (loss) for each period were as follows:
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Intel Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| CCG | DCAI | Total Intel Products | Intel Foundry | All Other | Corporate Unallocated | Intersegment Eliminations | Total Consolidated | |||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 8,535 | $ | 4,117 | $ | 12,652 | $ | 4,235 | $ | 993 | $ | — | $ | (4,227) | $ | 13,653 | ||||||||||||||||||||||||||||||||||
| Cost of sales and operating expenses | 5,841 | 3,153 | 8,994 | 6,556 | 893 | 782 | (4,255) | 12,970 | ||||||||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 2,694 | $ | 964 | $ | 3,658 | $ | (2,321) | $ | 100 | $ | (782) | $ | 28 | $ | 683 |
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Sep 28, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Intel Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| CCG | DCAI | Total Intel Products | Intel Foundry | All Other | Corporate Unallocated | Intersegment Eliminations | Total Consolidated | |||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 8,161 | $ | 4,141 | $ | 12,302 | $ | 4,339 | $ | 964 | $ | — | $ | (4,321) | $ | 13,284 | ||||||||||||||||||||||||||||||||||
| Cost of sales and operating expenses | 5,224 | 3,760 | 8,984 | 10,138 | 959 | 6,502 | (4,242) | 22,341 | ||||||||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 2,937 | $ | 381 | $ | 3,318 | $ | (5,799) | $ | 5 | $ | (6,502) | $ | (79) | $ | (9,057) |
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Intel Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| CCG | DCAI | Total Intel Products | Intel Foundry | All Other | Corporate Unallocated | Intersegment Eliminations | Total Consolidated | |||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 24,035 | $ | 12,182 | $ | 36,217 | $ | 13,319 | $ | 2,989 | $ | — | $ | (13,346) | $ | 39,179 | ||||||||||||||||||||||||||||||||||
| Cost of sales and operating expenses | 16,927 | 10,010 | 26,937 | 21,128 | 2,717 | 4,797 | (13,606) | 41,973 | ||||||||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 7,108 | $ | 2,172 | $ | 9,280 | $ | (7,809) | $ | 272 | $ | (4,797) | $ | 260 | $ | (2,794) |
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Sep 28, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Intel Products | ||||||||||||||||||||||||||||||||||||||||||||||||||
| CCG | DCAI | Total Intel Products | Intel Foundry | All Other | Corporate Unallocated | Intersegment Eliminations | Total Consolidated | |||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 24,577 | $ | 11,774 | $ | 36,351 | $ | 12,977 | $ | 2,488 | $ | — | $ | (12,975) | $ | 38,841 | ||||||||||||||||||||||||||||||||||
| Cost of sales and operating expenses | 16,177 | 10,734 | 26,911 | 24,019 | 2,699 | 10,397 | (13,095) | 50,931 | ||||||||||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 8,400 | $ | 1,040 | $ | 9,440 | $ | (11,042) | $ | (211) | $ | (10,397) | $ | 120 | $ | (12,090) |
![]() | Financial Statements | Notes to Financial Statements | 10 |
Corporate Unallocated Expenses
Corporate unallocated expenses include certain operating expenses not allocated to specific operating segments. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs.
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Acquisition-related costs | $ | 118 | $ | 266 | $ | 388 | $ | 796 | ||||||||||||||||||
| Share-based compensation | 548 | 800 | 1,896 | 2,759 | ||||||||||||||||||||||
| Restructuring and other charges1 | 175 | 5,622 | 2,221 | 6,913 | ||||||||||||||||||||||
| Other | (59) | (186) | 292 | (71) | ||||||||||||||||||||||
| Total corporate unallocated expenses | $ | 782 | $ | 6,502 | $ | 4,797 | $ | 10,397 |
1 See "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements for further information.
| Note 3 : | Non-Controlling Interests |
| Non-Controlling Ownership % | ||||||||||||||||||||
| Sep 27, 2025 | Sep 28, 2024 | |||||||||||||||||||
| Ireland SCIP | 49 | % | 49 | % | ||||||||||||||||
| Arizona SCIP | 49 | % | 49 | % | ||||||||||||||||
| Mobileye | 20 | % | 12 | % | ||||||||||||||||
| IMS | 32 | % | 32 | % |
| (In Millions) | Ireland SCIP | Arizona SCIP | Mobileye | IMS | Total | |||||||||||||||||||||||||||
| Non-controlling interests as of Dec 28, 2024 | $ | 61 | $ | 3,888 | $ | 1,672 | $ | 141 | $ | 5,762 | ||||||||||||||||||||||
| Partner contributions | — | 3,653 | — | — | 3,653 | |||||||||||||||||||||||||||
| Partner distributions | (159) | — | — | — | (159) | |||||||||||||||||||||||||||
| Changes in equity of non-controlling interest holders | — | — | 1,063 | — | 1,063 | |||||||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interests | 167 | (74) | (33) | (25) | 35 | |||||||||||||||||||||||||||
| Non-controlling interests as of Sep 27, 2025 | $ | 69 | $ | 7,467 | $ | 2,702 | $ | 116 | $ | 10,354 |
| (In Millions) | Ireland SCIP | Arizona SCIP | Mobileye | IMS | Total | |||||||||||||||||||||||||||
| Non-controlling interests as of Dec 30, 2023 | $ | — | $ | 2,359 | $ | 1,838 | $ | 178 | $ | 4,375 | ||||||||||||||||||||||
| Partner contributions | — | 1,266 | — | — | 1,266 | |||||||||||||||||||||||||||
| Changes in equity of non-controlling interest holders | — | — | 141 | — | 141 | |||||||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interests | 51 | (107) | (362) | (32) | (450) | |||||||||||||||||||||||||||
| Non-controlling interests as of Sep 28, 2024 | $ | 51 | $ | 3,518 | $ | 1,617 | $ | 146 | $ | 5,332 |
![]() | Financial Statements | Notes to Financial Statements | 11 |
Mobileye
On July 11, 2025, we converted 113.7 million of our Mobileye Class B shares into Class A shares. We subsequently sold 57.5 million of the Class A shares in a secondary offering, representing 7% of Mobileye's outstanding capital stock, for $16.50 per share and received net proceeds of $922 million. Concurrently, Mobileye repurchased from us 6.2 million of the Class A Shares for $16.50. As of September 27, 2025, we continue to hold the remaining 50.0 million Mobileye Class A shares from the conversion, in addition to our remaining Mobileye Class B shares. As we will continue to consolidate the results of Mobileye, the impact of their share repurchase was eliminated in our Consolidated Condensed Financial Statements. In the third quarter of 2024, we recognized a non-cash goodwill impairment charge of $2.8 billion, substantially all of which related to our Mobileye reporting unit. The non-cash impairment charge related to our Mobileye reporting unit was attributed to Intel and to non-controlling interest holders based on our proportional ownership (see "Note 11: Goodwill" within Notes to Consolidated Financial Statements as included in our 2024 Form 10-K for further information).
Semiconductor Co-Investment Program
Ireland SCIP
We consolidate the results of an Irish limited liability company (Ireland SCIP), a VIE, into our Consolidated Condensed Financial Statements because we are the primary beneficiary. Generally, distributions will be received from Ireland SCIP based on each investor's respective ownership of Ireland SCIP, of which Intel's is 51%. Ireland SCIP has rights to factory output of an Intel owned wafer fabrication plant in Ireland (Fab 34) and rights to resell the factory output to us. We retain sole ownership of Fab 34 and we are engaged as the Fab 34 operator in exchange for variable payments from Ireland SCIP based on the related factory output. We are required to substantially complete construction of Fab 34 in accordance with contractual parameters and timelines or we will be required to pay delay-related liquidated damages to Apollo, the other investor, beginning in 2026, not to exceed $1.1 billion in total. Though we expect certain construction delays in the near term, we intend to complete construction of Fab 34. We will be required to purchase minimum quantities of the related factory output from Ireland SCIP, or we will be subject to certain volume-related damages payable to Ireland SCIP, beginning at the earlier of when construction is complete or the third quarter of 2027. As of September 27, 2025, other than cash and cash equivalents held by Ireland SCIP, most of the remaining assets and liabilities of Ireland SCIP were eliminated in our Consolidated Condensed Balance Sheets.
Arizona SCIP
We consolidate the results of an Arizona limited liability company (Arizona SCIP), a VIE, into our Consolidated Condensed Financial Statements because we are the primary beneficiary. Contributions and distributions made between Arizona SCIP and investors are generally made based on our and Brookfield's proportional ownership interest in Arizona SCIP.
We are the primary beneficiary of two new chip factories still partially under construction by Arizona SCIP; we have the right to direct how and for what purpose the underlying assets will be used and to purchase 100% of the wafer output. During the three months ended September 27, 2025, Arizona SCIP placed the first tranche of manufacturing assets into service, making the assets available for our use. When production commences in 2026, as the sole operator we will be required to operate Arizona SCIP at minimum production levels and will be required to limit excess inventory held on site or we will be subject to certain volume-related damages payable to Arizona SCIP.
The property, plant, and equipment assets owned by Arizona SCIP and included in our Consolidated Condensed Balance Sheets as of September 27, 2025, which are not available to us as they can be used only to settle obligations of the VIE, consisted of construction in progress assets of $5.2 billion ($11.5 billion as of December 28, 2024) and assets that have been placed into service of $10.9 billion. The remaining assets and liabilities of Arizona SCIP were eliminated in our Consolidated Condensed Balance Sheets.
![]() | Financial Statements | Notes to Financial Statements | 12 |
| Note 4 : | Earnings (Loss) Per Share and Stockholders' Equity |
We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period, if applicable.
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions, Except Per Share Amounts) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Net income (loss) | $ | 4,270 | $ | (16,989) | $ | 359 | $ | (19,080) | ||||||||||||||||||
| Less: net income (loss) attributable to non-controlling interests | 207 | (350) | 35 | (450) | ||||||||||||||||||||||
| Net income (loss) attributable to Intel | $ | 4,063 | $ | (16,639) | $ | 324 | $ | (18,630) | ||||||||||||||||||
| Weighted average shares of common stock outstanding—basic****1 | 4,514 | 4,292 | 4,424 | 4,267 | ||||||||||||||||||||||
| Dilutive effect of employee equity incentive plans and stock issuances | 17 | — | 10 | — | ||||||||||||||||||||||
| Weighted average shares of common stock outstanding—diluted | 4,531 | 4,292 | 4,434 | 4,267 | ||||||||||||||||||||||
| Earnings (loss) per share attributable to Intel—basic | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) | ||||||||||||||||||
| Earnings (loss) per share attributable to Intel—diluted****2 | $ | 0.90 | $ | (3.88) | $ | 0.07 | $ | (4.37) |
1 For the three and nine months ended September 27, 2025, we have included the weighted average impacts of Escrowed Shares that are not contingently issuable. Refer to additional discussion under the Warrant and Common Stock Agreement with the U.S. government section below.
2 For the three and nine months ended September 27, 2025, earnings (loss) per share attributable to Intel-diluted has been calculated by adjusting net income (loss) attributable to Intel for the loss of $2 million related to the mark-to-market of that portion of the derivative liability that is attributable to 342 thousand contingent Escrowed Shares that were included in the weighted average shares of common stock outstanding-diluted during the period.
Potentially dilutive shares of common stock from employee equity incentive plans and stock issuances are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The dilutive impact from the assumed issuance of common stock associated with a contractual transaction to issue shares of common stock that settled in the three and nine months ended September 27, 2025 is determined from the date of the agreement or the beginning of the period (whichever is later) to the date the transaction closes by applying the treasury stock method firstly by calculating the weighted average shares for that period and secondly by reducing weighted average shares by the hypothetical buyback of shares calculated by dividing the total proceeds received by the average market price of Intel stock for the period. The potentially dilutive impact from the assumed issuance of the Escrowed Shares is determined by applying the if-converted method to the weighted average shares from the equity agreement date or the beginning of the period (whichever is later) to the date we received proceeds from Secure Enclave (defined below), as applicable to each period in which Secure Enclave proceeds are received. The potentially dilutive impact from the assumed issuance of common stock associated with a contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature.
In the three and nine months ended September 27, 2025 and September 28, 2024, securities that would have been anti-dilutive were insignificant.
Sales of Common Stock
Private Placement Share Sale to SoftBank Group
On August 18, 2025, we entered into an agreement to issue and sell 87 million shares of our common stock to SoftBank Group at $23.00 per share, representing an aggregate cash purchase price of $2.0 billion. The transaction closed on September 26, 2025.
![]() | Financial Statements | Notes to Financial Statements | 13 |
U.S. Government Agreements
On August 22, 2025, we entered into a Warrant and Common Stock Agreement (U.S. Government Agreement) with the U.S. Department of Commerce (DOC). Pursuant to the terms of the U.S. Government Agreement, the Federal Government of the United States of America (U.S. government) agreed to make disbursements to us consisting of (1) the acceleration of certain disbursements under an amendment to our November 2024 Direct Funding Agreement (DFA) under the CHIPs and Science Act of 2022 (CHIPs Act) with the DOC in the amount of $5.7 billion and (2) $3.2 billion of disbursements in respect of our existing agreement with the U.S. government under the CHIPs Act Secure Enclave program (Secure Enclave) to be made as we perform on our commitments pursuant to the terms and conditions of Secure Enclave. As compensation to the U.S. government for, and as a condition to the DOC's willingness to permit, the disbursements, the company agreed to issue to the DOC: (i) up to 433 million shares of our common stock, of which 275 million would be issued on the closing date (Common Stock Issuance) and 159 million would be issued into escrow to be released as disbursements are received by us under Secure Enclave (Escrowed Shares); and (ii) warrants exercisable to purchase up to 241 million shares of our common stock at $20.00 per share (Warrants) if we were to cease to directly or indirectly own at least 51% of our foundry business (Warrant Condition). The DOC also agreed that to the maximum extent permissible under applicable law, our obligations pursuant to the DFA would be considered discharged, other than with respect to Secure Enclave. The U.S. government agreed to make the disbursements in respect of, and on the terms and conditions of, Secure Enclave and agreed to work with us to make appropriate amendments and modifications to the DFA to release us from certain of its obligations.
On August 27, 2025, the closing of the transactions contemplated by the U.S. Government Agreement occurred. On such date:
▪we and the DOC entered into an amendment to the DFA that, among other things, removed the prior project milestone requirements and certain other conditions to disbursements under the DFA;
▪we received from the DOC the $5.7 billion of remaining potential disbursements under the DFA;
▪we issued to the DOC the 275 million share Common Stock Issuance;
▪we issued to the DOC the Warrants to purchase up to 241 million shares of our common stock, subject to anti-dilution adjustments for dividends, distributions, subdivisions, combinations or reclassifications; and
▪we issued into escrow the 159 million Escrowed Shares for the benefit of the DOC to be released as the company performs, invoices and receives disbursements from the U.S. government under Secure Enclave.
The Escrowed Shares will be released from escrow as and when Secure Enclave disbursements are received by us for our performance under Secure Enclave, with the number of Escrowed Shares to be issued with respect to each Secure Enclave disbursement being determined based on $20.00 per share. To the extent any Escrowed Shares have not been released from escrow at the end of the period during which we are eligible for Secure Enclave disbursements, half of any remaining Escrowed Shares will be released from escrow to the DOC at such time with no additional consideration payable to us, with the other half of the remaining Escrowed Shares automatically forfeited and cancelled. During the three months ended September 27, 2025, we released 684 thousand Escrowed Shares pertaining to disbursement received under Secure Enclave.
We accounted for the $5.7 billion of accelerated disbursements under the amended DFA as being attributable to our issuance of three freestanding instruments: the 275 million share Common Stock Issuance, the 159 million Escrowed Shares, and the Warrants to purchase 241 million shares. We have concluded that the Common Stock Issuance and the issuance of the Warrants should be classified within permanent equity. We classified the Escrowed Shares as a derivative liability, which was recorded at fair value at inception with subsequent changes in fair value recorded through interest and other, net within our Consolidated Condensed Statements of Operations until settlement. Accordingly, we have allocated the $5.7 billion in cash proceeds received at the closing date to the Escrowed Shares at fair value of $3.9 billion, with the remaining proceeds allocated to the Common Stock Issuance and Warrants of $1.6 billion and $110 million, respectively, based on their relative fair values. During the three months ended September 27, 2025, we recognized $1.7 billion related to the net change in fair value of the Escrowed Shares as of the settlement date for Escrowed Shares that were released during the period and as of the reporting date for Escrowed Shares that were not released. At September 27, 2025, the fair value of the Escrowed Shares was $5.6 billion, which we have recognized within other accrued liabilities and other long-term liabilities.
The $2.3 billion previously received under the DFA and Secure Enclave programs prior to the August 22, 2025 U.S. Government Agreement date remained subject to our government grant accounting policy. See “Note 5: Other Financial Statement Details” within Notes to Consolidated Condensed Financial Statements for further discussion.
In the three and nine months ended September 27, 2025, we released 684 thousand Escrowed Shares upon our receipt of certain of the cash proceeds for our performance under Secure Enclave. The remaining 79 million Escrowed Shares that were not contingently issuable based on the terms of the U.S. Government Agreement have been included in our computation of basic earnings per share for the three and nine months ended September 27, 2025. The remaining 79 million Escrowed Shares are considered contingently issuable based on the DOC's disbursements under Secure Enclave and therefore will be excluded from basic and diluted earnings per share until the contingencies are met. Potentially dilutive shares issuable under the Warrant have been excluded from all basic and diluted earnings per share calculations for the three and nine months ended September 27, 2025 as the Warrants are neither currently nor expected to become exercisable.
![]() | Financial Statements | Notes to Financial Statements | 14 |
Private Placement Share Sale to NVIDIA
On September 15, 2025, we entered into an agreement to issue and sell 215 million shares of our common stock to NVIDIA at a price of $23.28 per share, representing an aggregate cash purchase price of $5.0 billion. The closing of the issuance and sale, which represents a standalone transaction, remains subject to customary closing conditions.
| Note 5 : | Other Financial Statement Details |
Accounts Receivable
We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $2.4 billion during the first nine months of 2025 ($1.5 billion during the first nine months of 2024). After the sale of our accounts receivable, we collect payment from the customers and remit to the third-party financial institution.
Inventories
| (In Millions) | Sep 27, 2025 | Dec 28, 2024 | ||||||||||||
| Raw materials | $ | 1,135 | $ | 1,344 | ||||||||||
| Work in process | 6,751 | 7,432 | ||||||||||||
| Finished goods | 3,603 | 3,422 | ||||||||||||
| Total inventories | $ | 11,489 | $ | 12,198 |
Property, Plant, and Equipment
We invest in and deploy manufacturing assets in response to manufacturing capacity requirements based upon short- and long-term demand forecasts and economic returns relative to capital outlays. We regularly monitor, evaluate, and adjust our manufacturing capacity footprint in response to a number of volatile factors that impact our business, including demand for our products and services and the state of the semiconductor industry as a whole. In connection with the preparation of our Consolidated Condensed Financial Statements for the second quarter of 2025, we evaluated our current process technology node capacities relative to projected market demand for our products and services, concluding that our manufacturing asset portfolio exceeded manufacturing capacity requirements. Upon performing a re-use assessment, we impaired and accelerated depreciation for certain manufacturing assets. In total, we recorded non-cash impairments and accelerated depreciation charges of $460 million and $337 million, respectively, in the second quarter of 2025, net of certain items. All charges were recognized in cost of sales within our Intel Foundry operating segment. In the third quarter of 2024, we performed a similar exercise and recorded non-cash impairments and accelerated depreciation charges of $2.1 billion and $945 million, respectively, substantially all of which were recognized in cost of sales within our Intel Foundry operating segment.
Additionally, we incurred other non-cash asset impairment and accelerated depreciation charges of $416 million in the second quarter of 2025 and $442 million in the third quarter of 2024, as a direct result of the 2025 Restructuring Plan and 2024 Restructuring Plan, respectively (see "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements). These charges were included as a component of "corporate unallocated expenses" within the restructuring and other charges category for each applicable period, as presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements.
Other Accrued Liabilities
Other accrued liabilities include deferred compensation of $3.2 billion as of September 27, 2025 ($3.3 billion as of December 28, 2024).
Interest and Other, Net
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Interest income | $ | 228 | $ | 340 | $ | 682 | $ | 983 | ||||||||||||||||||
| Interest expense | (282) | (248) | (808) | (800) | ||||||||||||||||||||||
| Gain (loss) on mark-to-market of Escrowed Shares | (1,687) | — | (1,687) | — | ||||||||||||||||||||||
| Gain on divestiture of Altera | 5,546 | — | 5,546 | — | ||||||||||||||||||||||
| Other, net | (135) | 38 | (331) | 172 | ||||||||||||||||||||||
| Total interest and other, net | $ | 3,670 | $ | 130 | $ | 3,402 | $ | 355 |
Interest expense is net of $284 million of interest capitalized in the third quarter of 2025 and $964 million in the first nine months of 2025 ($392 million in the third quarter of 2024 and $1.1 billion in the first nine months of 2024).
![]() | Financial Statements | Notes to Financial Statements | 15 |
Gain (loss) on mark-to-market of Escrowed Shares related to changes in fair value of the Escrowed Shares released during the periods ended and held as of September 27, 2025 (refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements).
Gain on divestiture of Altera is related to the sale of 51% of the business for which we recorded a pretax gain of $5.5 billion (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements).
Other, net included charges of $97 million in the third quarter of 2025 and $191 million in the first nine months of 2025 related to the sale of our NAND memory business (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements).
Government Incentives
In the first nine months of 2025, we recognized $1.0 billion in grants under the CHIPs Act, of which capital-related incentives reduced gross property, plant and equipment by $769 million, and operating-related incentives benefited operating income by $236 million, substantially all of which was recorded in cost of sales. Of the $236 million operating grants recognized in the first nine months of 2025, $88 million was recognized in the third quarter of 2025*.* In the third quarter of 2025, our CHIPs Act grant was modified with grant amounts earned as of the modification date remaining subject to our government grant accounting policy (refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements). Additionally, in the first nine months of 2025 we recognized AMIC claims of $5.1 billion ($1.7 billion in the first nine months of 2024), which may be refunded to us in cash to the extent it exceeds our outstanding income tax liabilities.
| Note 6 : | Restructuring and Other Charges |
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Employee severance and benefit arrangements | $ | 146 | $ | 2,193 | $ | 1,754 | $ | 2,487 | ||||||||||||||||||
| Litigation charges and other | 33 | 36 | 52 | 814 | ||||||||||||||||||||||
| Asset impairment charges | (4) | 3,393 | 415 | 3,612 | ||||||||||||||||||||||
| Total restructuring and other charges | $ | 175 | $ | 5,622 | $ | 2,221 | $ | 6,913 |
In the second quarter of 2025, we announced and commenced the 2025 Restructuring Plan, which was subsequently approved and committed to by our management. This initiative is intended to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing lower-priority programs and initiatives. Restructuring charges are primarily comprised of employee severance and benefit arrangements, non-cash asset impairment and accelerated depreciation charges resulting from exit activities, as well as impairment charges relating to real estate exits and consolidations. These charges were included as "corporate unallocated expenses" within the restructuring and other charges category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. The total expected and cumulative cost of the 2025 Restructuring Plan as of September 27, 2025 was $1.9 billion. Any changes to our estimates or timing will be reflected in our results of operations in future periods. We expect a substantial majority of the actions pursuant to the 2025 Restructuring Plan to be complete by the fourth quarter of 2025, which is subject to change.
In the third quarter of 2024, the 2024 Restructuring Plan was announced and a series of cost and capital reduction initiatives were implemented. We have incurred total charges of approximately $3.1 billion under the 2024 Restructuring Plan, which was substantially complete in the second quarter of 2025.
Employee severance and benefit arrangements included net charges of $106 million and $1.5 billion during the three and nine months ended September 27, 2025 resulting from the 2025 Restructuring Plan. The remaining charges incurred during the three and nine months ended September 27, 2025 primarily related to the 2024 Restructuring Plan. Additionally, we incurred charges of $2.2 billion in the third quarter and first nine months of 2024 related to the 2024 Restructuring Plan. Charges relating to other actions taken to streamline operations and reduce costs were $294 million in the nine months ended September 28, 2024.
![]() | Financial Statements | Notes to Financial Statements | 16 |
Restructuring activities related to employee severance and benefit arrangements under the 2025 and 2024 Restructuring Plans were as follows:
| (In Millions) | 2025 Restructuring Plan | 2024 Restructuring Plan | ||||||||||||
| Accrued restructuring balance as of December 28, 2024 | $ | — | $ | 302 | ||||||||||
| Accruals and adjustments | 1,486 | 196 | ||||||||||||
| Cash payments | (881) | (462) | ||||||||||||
| Accrued restructuring balance as of September 27, 2025 | $ | 605 | $ | 36 |
The accrued restructuring balance as of September 27, 2025 and December 28, 2024 was recorded as a current liability within accrued compensation and benefits on the Consolidated Condensed Balance Sheets.
Litigation charges and other included a charge of $780 million in the second quarter of 2024 arising out of the R2 litigation. Refer to "Note 19: Commitments and Contingencies" within Notes to Consolidated Financial Statements as included in our 2024 Form 10-K for further information.
Asset impairment charges in the first nine months of 2025 primarily included $416 million of non-cash charges associated with the 2025 Restructuring Plan resulting from the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties. During the three and nine months ended September 28, 2024, we incurred cash and non-cash charges associated with the 2024 Restructuring Plan, including $442 million of non-cash impairments of construction in progress assets associated with our decision to exit and outsource manufacturing capabilities for certain internal test hardware; and $86 million of non-cash impairments of operating leased assets and related leasehold improvements resulting from real estate consolidations and exits.
In addition, we recorded non-cash goodwill impairment charges of $2.8 billion and $3.0 billion in the three and nine months ended September 28, 2024, respectively (see "Note 11: Goodwill" within Notes to Consolidated Financial Statements as included in our 2024 Form 10-K for further information). Further, in the third quarter of 2024, as a result of a decline in the actual and projected undiscounted cash flows for certain acquired intangible assets, we concluded the assets were not recoverable and recognized a non-cash impairment charge of $108 million. Goodwill and intangible asset impairment charges were included as "corporate unallocated expenses" within the restructuring and other charges category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements.
| Note 7 : | Income Taxes |
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| ($ In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Income (loss) before taxes | $ | 4,574 | $ | (9,086) | $ | 1,219 | $ | (11,809) | ||||||||||||||||||
| Provision for (benefit from) taxes | $ | 304 | $ | 7,903 | $ | 860 | $ | 7,271 | ||||||||||||||||||
| Effective tax rate | 6.6 | % | (87.0) | % | 70.5 | % | (61.6) | % |
In the three and nine months ended September 27, 2025, our provision for income taxes was determined using our estimated annual effective tax rate applied to our year-to-date ordinary income (loss) before taxes, adjusted for discrete items. We were not able to benefit from our current year domestic loss before taxes due to the domestic valuation allowance first established in the third quarter of 2024. Additionally, our financial statements as of September 27, 2025 and September 28, 2024 contain certain tax receivables of $2.7 billion and $845 million, respectively, within other current assets, and $5.3 billion and $1.7 billion, respectively, within other long-term assets associated with income tax overpayments and AMIC claims.
In the three and nine months ended September 28, 2024, due to our inability to reliably forecast our annual income, our provision for income taxes was determined using a three and nine month actual annual effective tax rate, respectively, adjusted for discrete items. In addition, we established a valuation allowance of $9.9 billion as a discrete non-cash tax expense against our U.S. deferred tax assets. We assess the recoverability of our deferred tax assets quarterly, weighing available positive and negative evidence. As a result of our assessment in the third quarter of 2024, we determined it was not more likely than not that the deferred tax assets will not be recoverable based upon our three-year cumulative historical loss position as of September 28, 2024, largely resulting from the asset impairment and restructuring and other charges incurred during that quarter.
On July 4, 2025, the One Big Beautiful Bill Act (the Act) was signed into law. The Act makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation and domestic research cost expensing, increases the AMIC credit rate to 35 percent from 25 percent for qualifying assets, and makes modifications to the international tax framework. The Act includes multiple effective dates, with certain provisions effective in 2025 and others phased in through 2027. We continue to evaluate the impact of the Act's provisions that take effect in future years.
![]() | Financial Statements | Notes to Financial Statements | 17 |
| Note 8 : | Investments |
Short-term Investments
Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Condensed Balance Sheets*.* Government debt includes instruments such as non-U.S. government bills and bonds and U.S. agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of September 27, 2025 and December 28, 2024, substantially all time deposits were issued by institutions outside the US.
For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net. The fair value of our economically hedged marketable debt investments was $19.1 billion as of September 27, 2025 ($13.5 billion as of December 28, 2024). For hedged investments still held at the reporting date, we recorded net losses of $47 million in the third quarter of 2025 and net gains of $416 million in the first nine months of 2025 (net gains of $406 million in the third quarter of 2024 and net gains of $195 million in the first nine months of 2024).
Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) and realized gains or losses recorded in interest and other, net. The adjusted cost of our unhedged investments was $6.8 billion as of September 27, 2025 ($5.2 billion as of December 28, 2024), which approximated the fair value at these dates.
The fair values of marketable debt investments, by contractual maturity, as of September 27, 2025, were as follows:
| (In Millions) | Fair Value | |||||||
| Due in 1 year or less | $ | 7,452 | ||||||
| Due in 1 – 2 years | 7,233 | |||||||
| Due in 2 – 5 years | 6,926 | |||||||
| Due after 5 years | 188 | |||||||
| Instruments not due at a single maturity date1 | 4,099 | |||||||
| Total | $ | 25,898 |
1 "Instruments not due at a single maturity date" is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents.
Equity Investments
| (In Millions) | Sep 27, 2025 | Dec 28, 2024 | ||||||||||||
| Marketable equity investments1 | $ | 572 | $ | 848 | ||||||||||
| Non-marketable equity investments | 8,095 | 4,535 | ||||||||||||
| Total | $ | 8,667 | $ | 5,383 |
1 Most of our marketable equity investments are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
The components of gains (losses) on equity investments, net for each period were as follows:
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Unrealized gains (losses) on marketable equity investments | $ | 116 | $ | (198) | $ | (234) | $ | (168) | ||||||||||||||||||
| Unrealized gains (losses) on non-marketable equity investments1 | 17 | — | 490 | 48 | ||||||||||||||||||||||
| Impairment charges on non-marketable equity investments | (76) | (110) | (232) | (269) | ||||||||||||||||||||||
| Unrealized gains (losses) on equity investments, net | 57 | (308) | 24 | (389) | ||||||||||||||||||||||
| Realized gains (losses) on sales of equity investments, net | 164 | 149 | 587 | 315 | ||||||||||||||||||||||
| Gains (losses) on equity investments, net | $ | 221 | $ | (159) | $ | 611 | $ | (74) |
1 Unrealized gains (losses) on non-marketable investments includes observable price adjustments and our share of equity method investee gains (losses) and certain distributions.
In the first nine months of 2025, we recognized upward observable price adjustments for our non-marketable equity investments of $486 million within gains (losses) on equity investments, net, of which $396 million related to a single investee.
![]() | Financial Statements | Notes to Financial Statements | 18 |
Altera
In the third quarter of 2025, we closed the sale of Altera and retained a 49% interest in the business (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements). The carrying value of our non-marketable equity investment in Altera is classified within equity investments in the Consolidated Condensed Balance Sheets and was $3.2 billion as of September 27, 2025.
We provide semiconductor wafer manufacturing services to Altera, a related party, in accordance with a wafer manufacturing and sale agreement. Additionally, and in connection with the divestiture, we will be reimbursed for costs that we incur on behalf of Altera for certain corporate services delivered under a transition services agreement, which may include information technology, finance, supply chain, and other services provided on an interim basis.
| Note 9 : | Divestitures |
Altera Divestiture
On April 14, 2025, we signed a transaction agreement with SLP VII Gryphon Aggregator, L.P., an affiliate of Silver Lake Partners (SLP), to sell 51% of all issued and outstanding common stock of Altera, our wholly owned subsidiary as of that date. On September 12, 2025, we completed the divestiture of 51% of Altera for net purchase consideration of $4.3 billion, consisting of: $4.3 billion in cash proceeds received at the closing, subject to working capital adjustments and other adjustments under the terms of the transaction agreement, separation agreement, and certain ancillary agreements attached to the transaction; $500 million in deferred cash proceeds also received within the third quarter of 2025; $500 million in deferred cash proceeds payable to us no later than December 31, 2027; an offset of $400 million for cash transferred to Altera with the sale; an offset of approximately $469 million in separation and employee-related costs we have agreed to fund to SLP; and an offset for other direct and incremental costs incurred in connection with the sale.
At September 27, 2025, we recognized a receivable of $457 million within other long-term assets for the present value of deferred consideration, which is not subject to any contingencies, and recognized $322 million and $132 million within other accrued liabilities and other long-term liabilities, respectively, for amounts payable to SLP for separation and employee-related costs that have not yet been paid and that relate to the transaction. We are in the process of finalizing the working capital adjustments and other customary closing adjustments with SLP which may result in adjustments to the final net cash proceeds received related to, and our gain on sale for, the transaction.
Upon closing the transaction, we retained a 49% minority investment in Altera, which is accounted for under the equity method of accounting. We established the fair value of our non-marketable equity investment in reference to Altera's equity value per the terms of the transaction agreement as the transaction negotiated with SLP represented an orderly transaction between market participants. The $3.2 billion value of our non-marketable equity investment in Altera is classified within equity investments in the Consolidated Condensed Balance Sheet at September 27, 2025 and recognized as a non-cash investing activity in the first nine months of 2025. We classify non-marketable equity investments, including equity method investments, as a Level 3 measurement.
Based on the terms of the transaction agreement with SLP, we have concluded that Altera is a VIE for which we are not the primary beneficiary because the governance structure of the entity does not allow us to direct the activities that most significantly impact Altera's economic performance. In line with this conclusion, we deconsolidated Altera from our consolidated financial statements at the September 12, 2025 transaction close date.
The carrying amounts of the major classes of Altera's net assets that we sold as of the September 12, 2025 transaction close date included the following:
| (In Millions) | ||||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 400 | ||||||
| Inventories | 673 | |||||||
| Property, plant and equipment, net | 198 | |||||||
| Identified intangible assets, net | 394 | |||||||
| Goodwill | 781 | |||||||
| Other assets | 316 | |||||||
| Total assets | $ | 2,762 | ||||||
| Liabilities | ||||||||
| Accrued compensation and benefits | $ | 182 | ||||||
| Other liabilities | 218 | |||||||
| Total liabilities | $ | 400 |
![]() | Financial Statements | Notes to Financial Statements | 19 |
Our sale of a 51% controlling stake in Altera, which is partially offset by the cash sold with Altera, separation and employee-related costs we agreed to fund to SLP, as well as direct and incremental costs we incurred to sell the business, resulted in a pre-tax gain of $5.5 billion recognized within interest and other, net. Our pre-tax gain was calculated as follows:
| (In Millions) | ||||||||||||||
| Proceeds from divestiture, net of cash sold and direct selling costs | $ | 4,266 | ||||||||||||
| Deferred consideration1 | 457 | |||||||||||||
| Fair value of retained interest in Altera1 | 3,246 | |||||||||||||
| Less: net assets of Altera, net of cash sold | (1,962) | |||||||||||||
| Less: separation and employee-related costs and other1 | (461) | |||||||||||||
| Gain on divestiture of Altera | $ | 5,546 |
1 Certain aspects of the net purchase consideration have yet to result in cash inflows and outflows and therefore reflect non-cash investing and financing activities within our Consolidated Condensed Statements of Cash Flows for the three and nine months ended September 27, 2025.
Approximately $2.1 billion of the gain resulted from the remeasurement of our non-marketable equity investment in Altera to its fair value at the transaction close date. Cash proceeds received within the third quarter of 2025 of $4.3 billion, net of the cash sold and the costs incurred to sell the business, are presented in net cash provided by (used for) investing activities, in the Consolidated Condensed Statements of Cash Flows for the nine months ended September 27, 2025.
NAND Memory Business
We sold our NAND memory technology and manufacturing business to SK hynix Inc. (SK hynix) which we deconsolidated upon closing the first phase of the transaction on December 29, 2021. On March 27, 2025, we closed the second phase of the transaction, collected the outstanding receivable, and recorded proceeds of $1.9 billion within cash and cash equivalents, net of certain adjustments.
In connection with the second closing, we entered into a final release and settlement agreement with SK hynix primarily related to certain penalties associated with the manufacturing and sale agreement between us and SK hynix, recognizing a net charge of $94 million within interest and other, net for the amount paid to SK hynix during the first quarter of 2025. In addition, in the third quarter of 2025, we recognized an incremental charge of $97 million within interest and other, net as a result of a contingency for which we have indemnified SK hynix.
| Note 10 : | Borrowings |
In the first quarter of 2025, we settled $1.5 billion of our senior notes due March 2025. In the third quarter of 2025, we settled $2.3 billion of our senior notes due July 2025.
In the first quarter of 2025, we amended our 364-day $8.0 billion credit facility agreement to $5.0 billion, and the maturity date was extended by one year to January 2026. Neither of our revolving credit facilities had borrowings outstanding as of September 27, 2025 or December 28, 2024.
We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. In the first nine months of 2025, we borrowed $3.5 billion and settled $3.5 billion of our commercial paper and had no commercial paper outstanding as of September 27, 2025 or as of December 28, 2024. Borrowings under the commercial paper program are unsecured general obligations.
![]() | Financial Statements | Notes to Financial Statements | 20 |
| Note 11 : | Fair Value |
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
| Sep 27, 2025 | Dec 28, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measured and Recorded at Reporting Date Using | Fair Value Measured and Recorded at Reporting Date Using | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate debt | $ | — | $ | 944 | $ | — | $ | 944 | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||||||||||||||||||||
| Financial institution instruments¹ | 3,813 | 1,347 | — | 5,160 | 4,121 | 743 | — | 4,864 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Reverse repurchase agreements | — | 4,369 | — | 4,369 | — | 2,654 | — | 2,654 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Short-term investments: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate debt | — | 6,066 | — | 6,066 | — | 5,365 | — | 5,365 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Financial institution instruments¹ | 286 | 3,400 | — | 3,686 | 195 | 3,356 | — | 3,551 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Government debt² | 5,280 | 4,762 | — | 10,042 | 33 | 4,864 | — | 4,897 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative assets | 342 | 480 | — | 822 | 348 | 733 | — | 1,081 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Marketable equity investments | 572 | — | — | 572 | 848 | — | — | 848 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other long-term assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative assets | — | 1 | — | 1 | — | 1 | — | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total assets measured and recorded at fair value | $ | 10,293 | $ | 21,369 | $ | — | $ | 31,662 | $ | 5,545 | $ | 17,716 | $ | — | $ | 23,261 | ||||||||||||||||||||||||||||||||||||||||
| Liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other accrued liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative liabilities³ | $ | 2,058 | $ | 422 | $ | 119 | $ | 2,599 | $ | — | $ | 562 | $ | 134 | $ | 696 | ||||||||||||||||||||||||||||||||||||||||
| Other long-term liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative liabilities³ | 3,555 | 169 | 755 | 4,479 | — | 416 | 755 | 1,171 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total liabilities measured and recorded at fair value | $ | 5,613 | $ | 591 | $ | 874 | $ | 7,078 | $ | — | $ | 978 | $ | 889 | $ | 1,867 |
1**Level 1 investments consist of money market funds. Level 2 investments consist primarily of time deposits, notes, and bonds issued by financial institutions.
2**Level 1 investments consist primarily of U.S. Treasury securities. Level 2 investments consist primarily of non-U.S. government debt.
3**Level 1 derivative liabilities relate to Escrowed Shares held and equity contracts for our deferred compensation program. Level 3 derivative liabilities include liquidated damage provisions related to our Ireland SCIP arrangement.
Assets Measured and Recorded at Fair Value on a Non-Recurring Basis
Our non-marketable equity investments and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity investments during the period, we classify these assets as Level 3. Similarly, impairments recognized on our goodwill, intangible assets, and property, plant, and equipment are categorized as Level 3 within the fair value hierarchy as we utilize unobservable inputs such as prospective financial information, market segment growth rates, and discount rates in the fair value measurement process.
Our non-recurring fair value measurements include the valuation of our non-marketable equity investment in Altera on the September 12, 2025 transaction close date, which was classified as Level 3. See "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information.
Financial Instruments Not Recorded at Fair Value on a Recurring Basis
Financial instruments not recorded at fair value on a recurring basis include non-marketable equity investments that have not been remeasured or impaired in the current period, grants receivable, certain long-term receivables, and issued debt.
We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial assets approximates their carrying value. The aggregate carrying value of grants receivable as of September 27, 2025 was $1.0 billion (the aggregate carrying value of grants receivable as of December 28, 2024 was $1.7 billion).
![]() | Financial Statements | Notes to Financial Statements | 21 |
We classify the fair value of issued debt (excluding any commercial paper) as Level 2. The fair value of these instruments was $42.3 billion as of September 27, 2025 ($43.5 billion as of December 28, 2024).
| Note 12 : | Derivative Financial Instruments |
Volume of Derivative Activity
Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows:
| (In Millions) | Sep 27, 2025 | Dec 28, 2024 | ||||||||||||||||||
| Foreign currency contracts | $ | 20,967 | $ | 25,472 | ||||||||||||||||
| Interest rate contracts | 21,130 | 17,899 | ||||||||||||||||||
| Equity contracts1 | 2,507 | 2,593 | ||||||||||||||||||
| Total | $ | 44,604 | $ | 45,964 |
1 Relates to our deferred compensation program.
The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $9.7 billion as of September 27, 2025 and $12.0 billion as of December 28, 2024.
Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets
| Sep 27, 2025 | Dec 28, 2024 | |||||||||||||||||||||||||
| (In Millions) | Assets****1 | Liabilities****2 | Assets****1 | Liabilities****2 | ||||||||||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||||||||||||||
| Foreign currency contracts3 | $ | 177 | $ | 35 | $ | 40 | $ | 405 | ||||||||||||||||||
| Interest rate contracts | — | 299 | — | 582 | ||||||||||||||||||||||
| Total derivatives designated as hedging instruments | $ | 177 | $ | 334 | $ | 40 | $ | 987 | ||||||||||||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||||||||||||||
| Foreign currency contracts3 | $ | 193 | $ | 261 | $ | 510 | $ | 100 | ||||||||||||||||||
| Interest rate contracts | 111 | 115 | 184 | 25 | ||||||||||||||||||||||
| Equity contracts4 | 342 | 2 | 348 | — | ||||||||||||||||||||||
| Escrowed Shares | — | 5,611 | — | — | ||||||||||||||||||||||
| Ireland SCIP arrangement | — | 755 | — | 755 | ||||||||||||||||||||||
| Total derivatives not designated as hedging instruments | $ | 646 | $ | 6,744 | $ | 1,042 | $ | 880 | ||||||||||||||||||
| Total derivatives | $ | 823 | $ | 7,078 | $ | 1,082 | $ | 1,867 |
1**Derivative assets are recorded as other assets, current and long-term.
2**Derivative liabilities are recorded as other liabilities, current and long-term.
3**A substantial majority of these instruments mature within 12 months.
4**Relates to our deferred compensation program.
![]() | Financial Statements | Notes to Financial Statements | 22 |
Amounts Offset in the Consolidated Condensed Balance Sheets
Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows:
| Sep 27, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Gross Amounts Recognized | Gross Amounts Offset in the Balance Sheet | Net Amounts Presented in the Balance Sheet | Financial Instruments | Cash and Non-Cash Collateral Received or Pledged | Net Amount | ||||||||||||||||||||||||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative assets subject to master netting arrangements | $ | 710 | $ | — | $ | 710 | $ | (339) | $ | (371) | $ | — | ||||||||||||||||||||||||||||||||||||||
| Reverse repurchase agreements | 4,369 | — | 4,369 | — | (4,369) | — | ||||||||||||||||||||||||||||||||||||||||||||
| Total assets | $ | 5,079 | $ | — | $ | 5,079 | $ | (339) | $ | (4,740) | $ | — | ||||||||||||||||||||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative liabilities subject to master netting arrangements | $ | 643 | $ | — | $ | 643 | $ | (339) | $ | (325) | $ | (21) | ||||||||||||||||||||||||||||||||||||||
| Total liabilities | $ | 643 | $ | — | $ | 643 | $ | (339) | $ | (325) | $ | (21) |
| Dec 28, 2024 | ||||||||||||||||||||||||||||||||||||||
| Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||||||||||||||||||||||
| (In Millions) | Gross Amounts Recognized | Gross Amounts Offset in the Balance Sheet | Net Amounts Presented in the Balance Sheet | Financial Instruments | Cash and Non-Cash Collateral Received or Pledged | Net Amount | ||||||||||||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||||||||||||||
| Derivative assets subject to master netting arrangements | $ | 948 | $ | — | $ | 948 | $ | (269) | $ | (679) | $ | — | ||||||||||||||||||||||||||
| Reverse repurchase agreements | 2,654 | — | 2,654 | — | (2,654) | — | ||||||||||||||||||||||||||||||||
| Total assets | $ | 3,602 | $ | — | $ | 3,602 | $ | (269) | $ | (3,333) | $ | — | ||||||||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||||||||||||||
| Derivative liabilities subject to master netting arrangements | $ | 1,084 | $ | — | $ | 1,084 | $ | (269) | $ | (745) | $ | 70 | ||||||||||||||||||||||||||
| Total liabilities | $ | 1,084 | $ | — | $ | 1,084 | $ | (269) | $ | (745) | $ | 70 |
We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate.
Derivatives in Cash Flow Hedging Relationships
The before-tax net gains or losses attributed to the effective portion of cash flow hedges recognized in other comprehensive income (loss) were $7 million net losses in the third quarter of 2025 and $706 million net gains in the first nine months of 2025 ($609 million net gains in the third quarter of 2024 and $49 million net losses in the first nine months of 2024).
![]() | Financial Statements | Notes to Financial Statements | 23 |
Derivatives in Fair Value Hedging Relationships
The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows:
| Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Operations | ||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | ||||||||||||||||||||||
| Interest rate contracts | $ | 36 | $ | 345 | $ | 283 | $ | 225 | ||||||||||||||||||
| Hedged items | (36) | (345) | (283) | (225) | ||||||||||||||||||||||
| Total | $ | — | $ | — | $ | — | $ | — |
The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows:
| Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included | Carrying Amount of the Hedged Item Assets/(Liabilities) | Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) | |||||||||||||||||||||||||||
| (In Millions) | Sep 27, 2025 | Dec 28, 2024 | Sep 27, 2025 | Dec 28, 2024 | |||||||||||||||||||||||||
| Short-term debt | $ | (988) | $ | (2,214) | $ | 12 | $ | 36 | |||||||||||||||||||||
| Long-term debt | (8,460) | (9,201) | 287 | 546 | |||||||||||||||||||||||||
| Total | $ | (9,448) | $ | (11,415) | $ | 299 | $ | 582 |
Derivatives Not Designated as Hedging Instruments
The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Operations for each period were as follows:
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| (In Millions) | Location of Gains (Losses) Recognized in Income on Derivatives | Sep 27, 2025 | Sep 28, 2024 | Sep 27, 2025 | Sep 28, 2024 | |||||||||||||||||||||||||||
| Foreign currency contracts | Interest and other, net | $ | 108 | $ | (344) | $ | 4 | $ | 192 | |||||||||||||||||||||||
| Interest rate contracts | Interest and other, net | 23 | (127) | (62) | 24 | |||||||||||||||||||||||||||
| Escrowed Shares | Interest and other, net | (1,687) | — | (1,687) | — | |||||||||||||||||||||||||||
| Other | Various | 167 | 97 | 209 | 290 | |||||||||||||||||||||||||||
| Total | $ | (1,389) | $ | (374) | $ | (1,536) | $ | 506 |
$1.7 billion of losses for the three and nine months ended September 27, 2025 related to changes in fair value of the Escrowed Shares released during the periods ended and held as of September 27, 2025 (refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements).
![]() | Financial Statements | Notes to Financial Statements | 24 |
| Note 13 : | Contingencies |
Legal Proceedings
We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. As of September 27, 2025, we have accrued a charge of $1.0 billion related to litigation involving VLSI and a charge of $401 million related to an EC-imposed fine, both as described below. Excluding the VLSI claims described below, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time.
European Commission Competition Matter
In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009.
We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC's 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court's January 2022 decision did not annul the EC's 2009 finding that we made payments to prevent sales of specific rival products.
In April 2022, the EC appealed the General Court's findings regarding rebates to the Court of Justice. In October 2024, the Court of Justice dismissed the EC's appeal, upholding the judgment of the General Court.
In September 2023, the EC imposed a €376 million ($401 million) fine against us based on its 2009 finding that we made payments to prevent sales of specific rival products. We have appealed the EC's decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings.
Litigation Related to Security Vulnerabilities
In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, the first variants of which are now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available.
Consumer class action lawsuits are pending against us in the U.S. and Canada. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with Spectre, Meltdown, and other variants of this class of security vulnerabilities that have been identified since 2018, and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the U.S., class action suits filed in various jurisdictions between 2018 and 2021 were consolidated for all pretrial proceedings in the U.S. District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs' failure to plead a viable claim. The Ninth Circuit Court of Appeals affirmed the district court's judgment in November 2023, ending the litigation. In November 2023, new plaintiffs filed a consumer class action complaint in the U.S. District Court for the Northern District of California with respect to a further vulnerability variant disclosed in August 2023 and commonly referred to as “Downfall.” In August 2024, the district court dismissed plaintiffs' entire complaint for failure to plead a viable claim, with leave to amend. In August 2025, the district court dismissed with prejudice the nationwide class claims under California law in plaintiffs' amended complaint, and denied Intel's motion to dismiss subclass claims pleaded in the alternative under the laws of certain other states. In October 2025 plaintiffs filed a second amended complaint. In Canada, an initial status conference has not yet been scheduled in one case relating to Spectre and Meltdown pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters.
![]() | Financial Statements | Notes to Financial Statements | 25 |
Litigation Related to Segment Reporting and Internal Foundry Model
A securities class action lawsuit was filed in the U.S. District Court for the Northern District of California in May 2024 against us and certain officers following the modification of our segment reporting in the first quarter of 2024 to align to our new internal foundry operating model. In August 2024, the court ordered the case consolidated with a second, similar lawsuit, and in October 2024 plaintiffs filed an amended consolidated complaint generally alleging that defendants violated the federal securities laws by making false or misleading statements about the growth and prospects of the foundry business and seeking monetary damages on behalf of all persons and entities that purchased or otherwise acquired our common stock or purchased call options or sold put options on our common stock from January 25, 2024 through August 1, 2024. In March 2025, the court dismissed plaintiffs' amended consolidated complaint, finding that plaintiffs failed to plead any false or misleading statements by defendants. The court granted plaintiffs leave to amend, but in July 2025 dismissed plaintiffs' second amended complaint and entered judgment in defendants' favor, again finding that plaintiffs failed to plead any false or misleading statements. Plaintiffs have appealed. Given the procedural posture of the case, including that the plaintiffs have appealed the district court's decision, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter.
Stockholder derivative lawsuits have been filed in Delaware state and federal courts alleging that our directors and certain officers breached their fiduciary duties and violated the federal securities laws by making or allowing the statements that are challenged in the securities class action lawsuit. The plaintiffs in the derivative lawsuits seek to recover damages from the defendants on behalf of Intel. The cases are stayed pending developments in the securities class action lawsuit.
Litigation Related to Patent and IP Claims
We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business.
VLSI Technology LLC v. Intel
In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the U.S. District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents VLSI acquired from NXP Semiconductors, N.V. (NXP). VLSI sought damages, attorneys' fees, costs, and interest. Intel prevailed on all eight patents and the court entered final judgment in April 2024. VLSI appealed the Court's judgment of non-infringement as to one of the eight patents. In April 2019, VLSI filed three infringement suits against us in the U.S. District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP:
▪The first Texas case went to trial in February 2021, and the jury awarded VLSI $1.5 billion for literal infringement of one patent and $675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI $2.2 billion in damages and approximately $162 million in pre-judgment and post-judgment interest. We appealed the judgment to the Federal Circuit Court of Appeals, including the court's rejection of Intel's claim to have a license from Fortress Investment Group's acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2023, the Federal Circuit reversed the finding of infringement as to the patent for which VLSI was awarded $675 million. The Federal Circuit affirmed the finding of infringement as to the patent for which VLSI had been awarded $1.5 billion, but vacated the damages award and sent the case back to the trial court for further damages proceedings on that patent. The Federal Circuit also ruled that Intel can advance the defense that it is licensed to VLSI's patents. In December 2021 and January 2022 the Patent Trial and Appeal Board (PTAB) instituted Inter Partes Reviews (IPR) on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB's decisions. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents. The motion remains pending.
▪The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately $3.0 billion for alleged infringement, plus enhanced damages for willful infringement. In September 2024, the court denied VLSI's motion for a new trial. Other post-trial motions remain pending, and the court has not yet entered final judgment.
![]() | Financial Statements | Notes to Financial Statements | 26 |
▪The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately $949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents, and the court granted Intel's motion that same month. In May 2025, the court held a trial on an underlying factual question relating to Intel’s license defense. The jury returned a verdict in Intel's favor. Post-trial briefing is complete, and the court will address the ultimate legal issue of whether Intel obtained a license to the asserted VLSI patent through Intel’s license agreement with Finjan when Fortress Investments acquired Finjan.
In May 2019, VLSI filed a case in Shenzhen Intermediate People's Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserted one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021 and September 2023. VLSI sought an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In November 2023, the trial court dismissed VLSI's case.
In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel Core processors. The Shanghai court held trial hearings in December 2020 and in May 2022, where VLSI requested expenses (RMB 300 thousand) and an injunction. In October 2023, the Shanghai court issued a decision finding no infringement and dismissing all claims. In November 2023, VLSI appealed the finding of non-infringement to the Supreme People's Court. The Supreme People's Court held an evidentiary hearing in October 2024, and a trial in November 2024.
In parallel in December 2022, we had filed a petition to invalidate the patent at issue in the Shanghai proceeding. In February 2024, the patent was found not invalid, and Intel appealed the decision in May 2024. After the Beijing Intellectual Property Court upheld the validity of the patent in May 2025, we filed a further appeal to the Supreme People’s Court in June 2025. Both VLSI’s appeal of the noninfringement decision and our appeal of the validity decision before the Supreme People’s Court remain pending.
In July 2024, Intel filed suit against VLSI in U.S. District Court for the District of Delaware requesting the court find Intel is licensed to VLSI's patents. In September 2024, VLSI filed motions requesting that Intel's complaint be dismissed, transferred, or stayed. In December 2024, the Delaware court stayed the case and deferred the pending motions until May 31, 2025. The Delaware court has not taken further action and continues to receive status reports from the parties regarding the Texas court's consideration of Intel's license defense.
As of September 27, 2025, we have accrued a charge of approximately $1.0 billion related to the VLSI litigation. We are unable to make a reasonable estimate of losses in excess of recorded amounts.
Eire Og Innovations v IBM et. al.
Since April 2024, EireOg Innovations Ltd. has filed eleven separate complaints in the Eastern and Western Districts of Texas against Intel and AMD customers alleging that various products with Intel and AMD CPUs infringe numerous patents. EireOg seeks compensatory damages, future royalties, attorneys’ fees, costs, and interest. Intel is indemnifying Acer, Amazon Web Services (AWS), Cisco Systems, Inc. (Cisco), Dell Technologies, Inc. (Dell), Hewlett Packard Enterprise (HPE), HP, Inc. (HPI), International Business Machines Corporation (IBM), Lenovo Group Ltd. (Lenovo), and Oracle Corporation (Oracle) in connection with Intel CPUs accused of infringing four patents. Cisco and IBM filed their answers in June 2024. In these cases, a Markman hearing was scheduled for August 2025, and trial is scheduled for February 2026. Dell and Oracle filed their answers in June and September 2024, respectively. The Markman hearing in those matters was held in May 2025, and trial is scheduled for June 2026. Lenovo filed a motion to dismiss for lack of jurisdiction in July 2024, which was denied, and it subsequently filed an answer in October 2024. HPE filed its answer in July 2024. Trial in the Lenovo and HPE matters is scheduled for March 2026. AWS moved to dismiss the complaint in June 2025, and EireOg responded with an amended complaint. AWS filed a motion to dismiss the amended complaint in July 2025, which was denied, and it subsequently filed an answer in October 2025. The Markman hearing in the AWS matter is scheduled for December 2025, and trial is scheduled for December 2026. In September 2025, EireOg filed joint motions to dismiss the claims against Acer and HPI without prejudice. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters.
Media Content Protection v Intel
In September 2020, Koninklijke Philips N.V. and Philips North America LLC (collectively, Philips) filed against Intel and customers in the U.S. District Court for the District of Delaware and the International Trade Commission (ITC). Philips alleged that certain Intel digital video-capable integrated circuits and associated firmware infringed two of its patents, including integrated circuits and associated firmware incorporated into products sold by Dell., HPI, Lenovo, and LG Electronics Inc. In March 2022, the ITC issued a final determination concluding that Philips had not proven a violation. Philips did not appeal the ITC’s decision, and a stay of the Delaware cases was lifted. Philips then sold the asserted patents to Media Content Protection (MCP) in July 2024, and MCP substituted in as the plaintiff. Trial is set for January 2026. MCP seeks $66 million to $398 million in damages for royalties between the 2020 case filing and the 2023 patent expiration date. Given the procedural posture and the nature of this case, including that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from this matter.
![]() | Financial Statements | Notes to Financial Statements | 27 |
| Key Terms | |||||
We use terms throughout our document that are specific to Intel or that are abbreviations that may not be commonly known or used. Below is a list of these terms used in our document.
| Term | Definition | |||||||||||||
| 2024 Restructuring Plan | Cost and capital reduction initiatives approved by management, the board of directors or the Audit & Finance Committee of the board of directors designed to adjust spending to current business trends and achieve objectives announced in Q3 2024 with respect to reducing operating expenses, reducing capital expenditures and reducing cost of sales while enabling Intel's new operating model and continuing to fund investments in Intel's core strategy | |||||||||||||
| 2025 Restructuring Plan | Transformational initiative announced and subsequently approved in Q2 2025 by our management to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing investment in lower-priority programs and initiatives | |||||||||||||
| AI | Artificial intelligence | |||||||||||||
| Altera | Altera Corporation, a business offering programmable semiconductors, primarily FPGAs, and related products for a broad range of applications. | |||||||||||||
| AMIC | Advanced Manufacturing Investment Credit | |||||||||||||
| Apollo | Apollo Global Management, Inc. | |||||||||||||
| ASP | Average selling price | |||||||||||||
| Brookfield | Brookfield Asset Management | |||||||||||||
| CCG | Client Computing Group operating segment | |||||||||||||
| CHIPs Act | Creating Helpful Incentives to Produce Semiconductors for America Act | |||||||||||||
| CODM | Chief operating decision maker | |||||||||||||
| CPU | Processor or central processing unit | |||||||||||||
| DCAI | Data Center and Artificial Intelligence operating segment | |||||||||||||
| DOC | U.S. Department of Commerce | |||||||||||||
| EC | European Commission | |||||||||||||
| EPS | Earnings per share | |||||||||||||
| Escrowed Shares | Shares of Intel common stock held in escrow to be released to the DOC as we perform and receive cash proceeds in connection with Secure Enclave | |||||||||||||
| 2024 Form 10-K | Annual Report on Form 10-K for the year ended December 28, 2024 | |||||||||||||
| FPGA | Field-programmable gate array | |||||||||||||
| IDM | Integrated device manufacturer, a semiconductor company that both designs and builds chips | |||||||||||||
| IMS | IMS Nanofabrication GmbH, a business within Intel Foundry that develops and produces electron-beam systems for the semiconductor industry | |||||||||||||
| IP | Intellectual property | |||||||||||||
| MD&A | Management's Discussion and Analysis | |||||||||||||
| MG&A | Marketing, general, and administrative | |||||||||||||
| NAND | NAND flash memory | |||||||||||||
| NEX | Networking and Edge operating segment | |||||||||||||
| Q1 2025 Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended March 29, 2025 | |||||||||||||
| Q2 2025 Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended June 28, 2025 | |||||||||||||
| R&D | Research and development | |||||||||||||
| RSU | Restricted stock unit | |||||||||||||
| SCIP | Semiconductor Co-Investment Program | |||||||||||||
| SEC | US Securities and Exchange Commission | |||||||||||||
| Secure Enclave | Secure Enclave program under the CHIPs Act | |||||||||||||
| SoC | System on a chip, which integrates most of the components of a computer or other electronic system into a single silicon chip. We offer a range of SoC products across many market segments for a variety of applications. | |||||||||||||
| SoftBank Group | SoftBank Group Corp | |||||||||||||
| U.S. | United States | |||||||||||||
| U.S. GAAP | U.S. Generally Accepted Accounting Principles | |||||||||||||
| VIE | Variable interest entity | |||||||||||||
![]() | Financial Statements | Notes to Financial Statements | 28 |
Previous: Cover and table of contents · Next: Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
